Amgen Inc

Amgen Inc (NASDAQ: AMGN) is a biotechnology company engaged in the discovery, development, manufacturing, and commercialization of therapies for serious and complex diseases. The company concentrates on areas with significant unmet medical needs, applying its scientific expertise to develop treatments aimed at improving patient outcomes. Its operations are conducted primarily within the human therapeutics segment.

Key Growth Aspects

• Broad-Based Revenue Expansion Driven by Volume Growth: Amgen delivered a robust operational performance in Q3 FY2025, with total revenues increasing 12% year-on-year to USD 9.6 billion, primarily supported by strong prescription demand across its portfolio. Product sales growth was underpinned by 14% volume expansion, reflecting sustained physician adoption and expanded patient access across key therapeutic areas. Notably, sixteen products achieved double-digit year-on-year sales growth, highlighting the breadth and resilience of the company’s commercial franchise.
• Strength in Core Growth Brands Across Therapeutic Areas: The company’s growth trajectory was reinforced by standout performances from flagship products. Repatha recorded a 40% year-on-year increase in sales to USD 794 million, driven by strong volume momentum following positive cardiovascular outcomes data. EVENITY and TEZSPIRE also posted robust growth of 36% and 40%, respectively, supported by expanding clinical indications and favorable market penetration. Rare disease assets such as UPLIZNA and TAVNEOS further contributed double-digit growth, strengthening Amgen’s diversification across high-value specialty segments.
• Advancing Pipeline with Multiple Late-Stage Catalysts: Amgen continued to advance a deep and diversified pipeline focused on large unmet medical needs. The completion of enrollment in multiple Phase 3 MARITIME studies for MariTide in obesity and cardiometabolic indications represents a significant milestone, while positive Phase 3 VESALIUS-CV outcomes for Repatha materially enhance its long-term value proposition. Additional regulatory momentum, including FDA approval of TEZSPIRE in chronic rhinosinusitis with nasal polyps and upcoming PDUFA decisions for IMDELLTRA and UPLIZNA, supports sustained innovation-led growth.
• Strong Cash Generation and Capital Allocation Discipline: The company generated USD 4.2 billion of free cash flow during the quarter, reflecting strong operating leverage and disciplined working capital management. Amgen continued to strengthen its balance sheet by retiring USD 1.6 billion of debt in Q3 and USD 6.0 billion year-to-date, while maintaining a consistent dividend policy with a 6% year-on-year increase. These actions reinforce financial flexibility to fund R&D investments and future growth initiatives.

Growth Challenges

• Margin Compression from Elevated Operating Expenses: Despite revenue growth, profitability faced pressure as non-GAAP operating expenses increased 18% year-on-year in Q3 FY2025. Research and development spending rose sharply by 31%, driven by higher investment in late-stage clinical programs, particularly MariTide. While strategically important, this elevated cost base resulted in a 2.5 percentage point decline in non-GAAP operating margin to 47.1%, indicating near-term margin compression.
• Pricing Headwinds and Net Selling Price Erosion: Amgen continued to experience pricing pressure across several mature and competitive products. Overall product sales growth was partially offset by a 4% decline in net selling prices, reflecting the impact of payer mix changes, Medicare Part D redesign, and increased exposure to the 340B program. Key products such as Enbrel and AMJEVITA faced notable price erosion, weighing on topline quality despite volume growth.
• Declining Performance of Legacy and Biosimilar-Exposed Assets; Certain established products continued to underperform due to intensifying biosimilar competition. Enbrel sales declined 30% year-on-year to USD 580 million, primarily driven by lower net pricing, while KYPROLIS and LUMAKRAS posted mid-single-digit declines due to softer volumes. Additionally, management expects further erosion in products like Prolia and XGEVA as biosimilars gain traction in the U.S. market, presenting an ongoing structural headwind.
• One-Off Charges and Higher Effective Tax Rate: Reported earnings were negatively impacted by a USD 400 million Otezla intangible asset impairment charge during the quarter, reflecting revised long-term expectations for the asset. In parallel, the effective non-GAAP tax rate increased by 4.8 percentage points year-on-year, driven by changes in earnings mix, which further constrained bottom-line growth and diluted operating leverage benefits.

Key Risks

• Pricing and Reimbursement Pressure: Continued exposure to net selling price erosion from Medicare Part D redesign, higher 340B mix, and payer negotiations could weigh on revenue quality despite volume growth.
• Biosimilar and Competitive Threats: Accelerating biosimilar competition for mature products such as Enbrel, Prolia, and XGEVA may lead to sustained sales and margin erosion over the medium term.
• R&D Execution and Cost Risk: Elevated investment in late-stage clinical programs, particularly MariTide, increases execution risk and may continue to pressure operating margins if clinical or regulatory outcomes disappoint.

Technical Observation (on the daily chart):

AMGEN’s daily chart shows a constructive medium-term uptrend, with the stock consolidating after a strong rally and still trading above its rising 50-day moving average. The recent pullback toward the 20-day average suggests a cooling of momentum rather than a trend reversal, while the RSI in neutral territory indicates balanced conditions.

Amgen’s Q3 FY2025 performance reflects a balanced operating profile, combining solid topline momentum with emerging profitability and portfolio headwinds. The company delivered 12% year-on-year revenue growth driven by broad-based volume expansion across key growth brands such as Repatha, EVENITY and TEZSPIRE, alongside continued progress in a late-stage, innovation-rich pipeline and strong free cash flow generation. However, these positives were partially offset by margin compression from sharply higher R&D spending, ongoing pricing pressure across mature products, biosimilar-driven erosion in legacy franchises, and one-off impairment charges that weighed on earnings quality. Overall, Amgen demonstrated resilient commercial execution and strategic pipeline advancement, while near-term financial performance remains constrained by cost inflation and competitive dynamics.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given Amgen Inc (NASDAQ: AMGN) at the closing market price of USD 325.31 as of Dec 15,2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is December 15,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.